Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone.
about
Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agentsApplication of routine electronic health record databases for pharmacogenetic researchA stewardship intervention program for safe medication management and use of antidiabetic drugsPharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors.Influence of CYP2C8*2 on the pharmacokinetics of pioglitazone in healthy African-American volunteersCurrent clinical evidence on pioglitazone pharmacogenomics.Rosiglitazone Metabolism in Human Liver Microsomes Using a Substrate Depletion Method.PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8.Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes.Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters.Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help?Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment.Direct and quantitative evaluation of the major human CYP contribution (fmCYP) to drug clearance using the in vitro Silensomes™ model.Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8-Mediated Metabolism of Montelukast in Humans.Physiologically based pharmacokinetics model predicts the lack of inhibition by repaglinide on the metabolism of pioglitazone.The Role of CYP2C8 and CYP2C9 Genotypes in Losartan-Dependent Inhibition of Paclitaxel Metabolism in Human Liver Microsomes.Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone.Clarification of the Mechanism of Clopidogrel-Mediated Drug-Drug Interaction in a Clinical Cassette Small-dose Study and Its Prediction Based on In Vitro Information.
P2860
Q26751138-092245EB-9CF1-43C7-97E3-6649183E7F4AQ26864747-770846D1-920A-43F4-A918-FE6A94F8B1D4Q30659038-06056AC4-4079-410A-8417-CDF38A470B97Q35039274-10894F61-DC14-4E4B-A4D8-6E4D77C3D645Q37141923-8CC56436-F628-4FF5-99AA-B03F52163EDDQ37342358-B5698585-737C-46F0-AE27-06B56EA34574Q37653438-DA193E1D-CF7D-4B99-B9D3-A30BD7CEA9BAQ38130410-75B68A6D-B867-4F97-8D8C-918EC2F18C6DQ38455771-1EA0DB91-ADE4-41FA-9A49-D6636EB11059Q38684505-086AE4FA-FAF7-46F7-A407-06558369F05EQ38933872-74641A32-FC2B-48A1-9F63-4F737D41AD6CQ38958223-90821727-D6BA-443A-8511-52EE50447AFAQ46702584-6A14ECFE-EE70-44EC-B0B1-4544F1F6624EQ49345918-1DC65E71-0B42-4514-A137-44DE720E7178Q49685370-31A4DCC9-AA4A-4007-BBD9-CFF5BE7B4F88Q50864429-EBBD2D4D-0779-44BB-B357-38F5241BF253Q52903732-5962EDF3-EF9A-4DDA-B947-63E4B8014E46Q53086784-7E17BE16-0F5E-4B53-B175-FC4101BCD289Q54053216-06DEAC63-E4CB-4AA0-848E-C1F02591BAA3
P2860
Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Impact of the CYP2C8 *3 polymo ...... gemfibrozil and pioglitazone.
@ast
Impact of the CYP2C8 *3 polymo ...... gemfibrozil and pioglitazone.
@en
type
label
Impact of the CYP2C8 *3 polymo ...... gemfibrozil and pioglitazone.
@ast
Impact of the CYP2C8 *3 polymo ...... gemfibrozil and pioglitazone.
@en
prefLabel
Impact of the CYP2C8 *3 polymo ...... gemfibrozil and pioglitazone.
@ast
Impact of the CYP2C8 *3 polymo ...... gemfibrozil and pioglitazone.
@en
P2093
P2860
P1476
Impact of the CYP2C8 *3 polymo ...... gemfibrozil and pioglitazone.
@en
P2093
Alexander T Kanack
Charles W Hopley
Christina L Aquilante
David W A Bourne
Elizabeth B Daily
Joseph E Rower
Julie A Predhomme
Kyle P Hammond
Lane R Bushman
Lisa A Kosmiski
P2860
P304
P356
10.1111/J.1365-2125.2012.04343.X
P407
P577
2013-01-01T00:00:00Z